Table I.
Frequencies of antitumor CTLp's in vaccinated melanoma patients
| Antitumor CTLp frequencyb
|
|||||
|---|---|---|---|---|---|
| Patient | Vaccine antigens | Tumor regressiona | Anti-vaccine CTLp frequencyb | Before | After |
| CP64 | MAGE-3.A1c | + | 5 × 10−5 | 6 × 10−5 | 6 × 10−4 |
| EB81 | MAGE-3.A1dMAGE-1.A1 | + | 3 × 10−6
<3 × 10−7 |
3 × 10−4 | 3 × 10−3 |
| CP67 | MAGE-3.A1dMAGE-1.A1 | + | 3 × 10−7
<3 × 10−7 |
5 × 10−4 | 10−4 |
| BB132 | MAGE-3.A1dMAGE-1.A1 | − | 10−7
<3 × 10−7 |
2 × 10−3 | 2 × 10−3 |
| LB2269 | MAGE-4.A2eMAGE-10.A2 | − | <10−7
5 × 10−5 f |
6 × 10−4 | 6 × 10−4 |
a
Some evidence of tumor regression observed after vaccination as detailed in Materials and Methods.
b
Among blood CD8 lymphocytes. The anti-vaccine CTLp frequencies were measured by in vitro restimulation of PBMCs with the antigenic peptide in limiting dilution conditions followed by labeling with tetramers. Before and After stands for before and after vaccination.
c
15 injections of 300 µg of peptide without adjuvant.
d
Three injections of ALVAC-MAGE followed by three injections of peptides without adjuvant.
e
Three injections of 300 µg of each peptide with rIL-12.
f
A similar frequency was already present before vaccination.